Suresh Sureddi is a Psychiatry physician. OpenAlex indexes 9 publications with 246 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3920 Alma Dr
Plano, TX 750236748
Telephone
972-422-5939Provider last certified this registry record 30 Jan 2026.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Axsome Therapeutics, Inc.Program year2025111 payments$105,328openpaymentsdata.cms.gov ↗
- Alkermes, Inc.Program year2025101 payments$81,552openpaymentsdata.cms.gov ↗
- Otsuka America Pharmaceutical, Inc.Program year202570 payments$63,945openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Benzodiazepine25.2%Alprazolam40%Clonazepam36%Lorazepam15%Diazepam7%Temazepam2%Part D<11 patientsAtypical Antipsychotic23.1%Quetiapine Fumarate35%Aripiprazole17%Lybalvi9%Abilify Maintena6%Lurasidone Hcl5%Vraylar5%Abilify Asimtufii4%Quetiapine Fumarate Er4%Caplyta4%Invega Sustenna4%Clozapine3%Olanzapine3%Risperidone3%Part D<11 patients+ 17 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic
The Journal of Clinical Psychiatry
2020 - First controlled treatment trial of bipolar II hypomania with mixed symptoms: Quetiapine versus placebo
Journal of Affective Disorders
2013 - The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder
Deutsche Zeitschrift für Akupunktur
2011 - The Safety, Acceptability, and Effectiveness of Acupuncture as an Adjunctive Treatment for Acute Symptoms in Bipolar Disorder
The Journal of Clinical Psychiatry
2009 - A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression
Journal of Affective Disorders
2008
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”